93. 原発性胆汁性胆管炎
[臨床試験数:230,薬物数:215(DrugBank:51),標的遺伝子数:34,標的パスウェイ数:107

Searched query = "Primary biliary cholangitis", "Primary biliary cirrhosis", "PBC"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
2 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00844402
(ClinicalTrials.gov)
January 200613/2/2009Safety and Efficacy of Long-Term Treatment With Atorvastatin in Patients With Primary Biliary CirrhosisSafety and Efficacy of Long-Term Treatment With Atorvastatin in Patients With Primary Biliary CirrhosisPrimary Biliary Cirrhosis;HypercholesterolemiaDrug: AtorvastatinMedical University of GrazNULLCompleted18 Years70 YearsBoth40Phase 3Austria
2EUCTR2005-002160-28-AT
(EUCTR)
23/09/200519/08/2005Safety and efficacy of long-term treatment with atorvastatin in patients with primary biliary cirrhosisSafety and efficacy of long-term treatment with atorvastatin in patients with primary biliary cirrhosis Reduction of cardiovascular risk may become key for the management of PBC. Therefore information on safety and efficacy (lipid-lowering effects) of statins in chronic cholestatic disorders is essential. Moreover, the study will answer the open question whether long-term treatment with statins may have potential beneficial effects on the course of PBC.Trade Name: Sortis
Product Name: Sortis 10 mg
INN or Proposed INN: Atorvastatin
Medical University Graz,Department of Internal Medicine, Division of Gastroenterology and HepatologyNULLNot RecruitingFemale: yes
Male: yes
80Austria